Trial Profile
Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms FITNESS
- 03 Apr 2023 Results assessing Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis published in the Thorax.
- 30 Jul 2021 Status changed from recruiting to completed.
- 01 Sep 2017 Planned number of patients changed from 80 to 84.